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SARS-CoV-2, the virus that causes COVID-19 consists of several enzymes with essential functions within its
proteome. Here, we focused on repurposing approved and investigational drugs/compounds. We targeted seven
proteins with enzymatic activities known to be essential at different stages of the viral cycle including PLpro,
3CLpro, RdRP, Helicase, ExoN, NendoU, and 2′ -O-MT. For virtual screening, energy minimization of a crystal
structure of the modeled protein was carried out using the Protein Preparation Wizard (Schrodinger LLC 2020-1).
Following active site selection based on data mining and COACH predictions, we performed a high-throughput
virtual screen of drugs and investigational molecules (n = 5903). The screening was performed against viral
targets using three sequential docking modes (i.e., HTVS, SP, and XP). Virtual screening identified ~290 po
tential inhibitors based on the criteria of energy, docking parameters, ligand, and binding site strain and score.
Drugs specific to each target protein were further analyzed for binding free energy perturbation by molecular
mechanics (prime MM-GBSA) and pruning the hits to the top 32 candidates. The top lead from each target pool
was further subjected to molecular dynamics simulation using the Desmond module. The resulting top eight hits
were tested for their SARS-CoV-2 anti-viral activity in-vitro. Among these, a known inhibitor of protein kinase C
isoforms, Bisindolylmaleimide IX (BIM IX), was found to be a potent inhibitor of SARS-CoV-2. Further, target
validation through enzymatic assays confirmed 3CLpro to be the target. This is the first study that has showcased
BIM IX as a COVID-19 inhibitor thereby validating our pipeline.

1. Introduction
A novel coronavirus was first reported in Wuhan, the capital city of

the Hubei province in China in December of 2019 [1]. This pathogen has
been named SARS-CoV-2 [2] and the disease caused by it is named,
COVID-19 (Coronavirus Disease-2019). So far there have been 58

Abbreviations: CoronaVirus Disease-2019 (COVID-19), SARS Corona Virus2 (SARS-CoV-2); CAD, computer-aided drug design; ExoN, exoribonuclease; COACH,
Meta-server approach to protein-ligand binding site prediction; HTVS, high throughput virtual screening; MERS, Middle Eastern Respiratory Syndrome; PLpro,
Papain-like proteinase; 3CLpro, 3-Chymotrypsin-Like Protease; 2′ -O-MT, 2′ -O-Methyltransferase; MOA, mechanism of action; RdRP, RNA-directed RNA polymerase;
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million COVID-19 cases including 1.3 million deaths worldwide [3].
The genome of coronaviruses consists of a single-stranded, positivesense RNA, causing respiratory and enteric disease in mammals
including humans. This family of viruses consists of a large genome,
ranging from 28 to 32 kilobases [4]. Coronavirus family members are
organized into three subsets based on antigenic and genetic facets:
α-CoVs, β-CoVs, and γ-CoVs [5,6]. MERS-CoV, SARS-CoV, and SARSCoV-2 are all β-coronaviruses, where both SARS-CoV and CoV-2 are
derived from the lineage B and MERS-CoV is derived from the lineage C
β-coronavirus [7]. Interestingly, these viruses have similar genomic
structures with functional proteins encoded at the 5′ end, and structural
proteins encoded at the 3′ end of the genome [8]. β-Coronaviruses have
accessory proteins dispersed throughout their structural genes with both
SARS-CoV and SARS-CoV-2 having seven different accessory proteins,
while MERS-CoV has five different accessory proteins [4,8].
The discovery and development of novel compounds that specifically
target SARS-CoV-2 will require an extended period of preclinical testing
before they can enter clinical trials. Due to the lack of specific anti-SARSCoV-2 therapeutics, there is an urgent need for faster treatment options.
One approach is through screening already approved or experimental
drugs that could be repurposed for SARS-CoV-2. In this study, we have
used a multi-pronged drug discovery approach through rapid screening
that is in-line with the World Health Organization’s (WHO) guidance to
repurpose approved drugs having already demonstrated acceptable
safety profiles.

and COACH predictions, we performed high-throughput virtual
screening (HTVS) of compounds (n = 5903) approved by worldwide
regulatory bodies including the FDA secured from the Zinc database or
were advanced investigational molecules [11]. The screening was per
formed using the Virtual Screening Wizard [10] consisting of three
sequential docking modes (HTVS, SP, and XP). Preliminary in-silico
virtual screening identified 290 potential inhibitory compounds based
on criteria including energy, docking parameters, ligand and binding
site strain energies, and fit score. Compounds specific to each target
protein were further analyzed for binding free energy perturbation by
the molecular mechanics’ method using Prime MM-GBSA [10], followed
by refining the hits to the best 32 lead candidates. A top-scoring lead
from each target group was further subjected to a molecular dynamic
simulation (MDS) using the Desmond module [10] to validate the
screening pipeline (Overall Study Design; Fig. 1).
2.1. Drug repurposing for COVID-19
While drugs have initially been produced for use against a specific
target and disease, drug repurposing offers a new and faster approach to
initiate research-based methodologies. The utility of protein modeling
and molecular docking has shown that approved drugs specified for
certain indications can have a significant impact on other diseases [12].
For example, loperamide is an approved drug for controlling acute and
chronic diarrhea that has exhibited inhibition of the MERS-CoV repli
cation cycle [13]. Several studies are currently in progress exploring the
use of antiviral drugs that were approved for influenza, hepatitis C virus,
and human immunodeficiency virus (HIV) 1 against COVID-19, though
with limited efficacy as well as at least in some cases added morbidity
due to serious side effects. When a drug is repurposed with efficacy and
safety demonstrated for other diseases, the timeline to availability to the
patient population is reduced, the cost of production is lower, and the
distribution channels are already in place.

2. Rational study design
Enzymes generally have binding sites that recognize small molecules
and thus, are comparatively more druggable than non-enzymatic pro
teins. We have selected seven essential coronavirus enzymes as potential
targets, namely 3CLpro, PLpro, RdRP, Helicase, NendoU, ExoN, and 2OMT, and subjected them to virtual screenings (Fig. 2). Details of these
targets are described in the following sections below. The 3D structures
were accessed from among the available PDB X-ray crystal structures as
well as from predicted structures available from the I-Tasser server [9].
The energy minimizations and accompanying relaxations of 3D struc
ture models (crystal structures/modeled proteins) were carried out
using the Protein Preparation Wizard followed by a short 20 ns MD
simulation [10]. Following active site selection based on data mining

2.2. Identifying SARS-CoV-2 proteins as essential targets for repurposable
drugs
Out of many proteins (~29) known to be produced by the virus, there
are several critical non-structural proteins in SARS-CoV-2 that are
valuable targets for antiviral drugs as illustrated below.

Fig 1. Schematic road map of the overall study design. The protein models from various protein bank and other sources were optimized and relaxed by MD sim
ulations. The relaxed structures were then mapped for active site and used to generate GLIDE Grid for HT-virtual screen with world approved drug libraries. The top
10% of these compounds were subjected to high accuracy docking (SP/XP) which were then further refined to the top 10%. This was followed by a secondary
rescoring (GBSA). Top leads were subjected to MD simulations of the top compounds for each viral target tested as a methodological validation.
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Fig. 2. Graphical illustration of the SARS-CoV-2 life cycle along with target proteins used in HTVS. The infection cycle starts when the SARS-CoV-2 Spike protein
binds to the Human ACE2 receptor. An S1-induced post-stable S2 conformation allows either viral-host cell fusion (1a) or endocytosis (1b). Fusion directly allows the
viral RNA to enter the host cell (2), but endocytosis requires lysosomal degradation of coat and envelop for the release of viral nucleocapsid in the cytoplasm. The
large viral script is known to encode 29 viral proteins (3), including the 7 essential nonstructural proteins that are selected as targets in our paper. A replicase is used
to translate most of the viral genomic RNA to synthesize two replicase polyproteins, pp1a and pp1ab, and many small ORFs(4). The two major polyproteins are
processed by two proteases, PLpro and 3CLpro(5), generating 16 nonstructural proteins. ExoN possesses a viral exoribonuclease activity that acts on both ssRNA and
dsRNA in a 3′ to 5′ direction(9). Viral Helicase plays a critical role in viral replication by expediting appropriate folding (7). The enzyme 2′ -O-MT methylates the viral
2′ end which is important for the virion to avoid host recognition of their RNA (8). RdRP is involved in viral-host cell replication through catalyzing template
synthesis of polynucleotides in the 5′ to 3′ direction (7). NendoU is an Mn2+ dependent hexamer (dimer of trimer) enzyme with sparse functional information. The
most prominent theory regarding NendoU is that the activity of this protein is responsible for protein interference with the innate immune system. For viral assembly
of S, E, and M proteins in the endoplasmic reticulum, along with the N protein are combined with the (+) gRNA to become a helical nucleoprotein complex. They
assemble to form a virus particle in the endoplasmic reticulum-Golgi apparatus compartment, this particle is then excreted from the cell through budding mediated
by fusion of smooth-walled vesicles to the plasma membrane (11–12).

Fig. 3. Results of a 100 nano seconds (ns) MD simulation. (A) Root mean square deviations difference between the Main protease (3CLPro) and bound ligand BIM IX
(<4 Å). Graph obtained for RMSF value of ligand (purple line) from the protein back bone (green line). It revealed that there was a major conformational change of
the ligand at around 50 ns without loss of the ligand. This suggests two binding conformers of same ligand within the binding site. (B) Schematic 2D representation of
bound ligand interactions of BIM IX throughout the simulation. (C) Root mean square fluctuation between the binding site of target protein and interacting ligand.
(D) Critical protein ligand contacts of amino acid side chain residues with the interaction properties. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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In the coronaviridae family, a replicase is used to translate most of
the viral genomic RNA to synthesize two replicase polyproteins, pp1a
and pp1ab. These two polyproteins are processed by two proteases, (1)
Papain-Like Protease (PLpro) and (2), coronavirus 3-Chymotrypsin-Like
Protease (3CLpro), generating 16 nonstructural proteins [14–16]. This
proteolytic processing is essential for generating functional replication
complexes [17]. As such, both PLpro and 3CLpro are promising anti
viral targets and have already shown promise against COVID-19 in the
drug combination therapy using lopinavir-ritonavir. PLpro has a core
catalytic domain containing 316 amino acids. This protease cleaves the
N-terminal region of the polyprotein to generate three different
nonstructural proteins (1/2/3). PLpro is also suggested to have deubiquitinating activity, due to its structural similarities with cellular
de-ubiquitinating enzymes [18] (Fig. 2). The enzyme 3CLpro contains a
cysteine-histidine dimer within its active site that directs proteolytic
activity. This protease can cleave 11 different sites of the replicase
polyprotein to produce a mature protein that anchors replication/tran
scription complexes and releases mature NSPs. Structural analyses and
computational screening with 3CLpro as a target have shown promising
results for drug candidates against SARS-CoV [19,20].
(3) viral non-structural protein (nsp) 14: Nsp14. Nsp14 has been
implicated in SARS-CoV-2 as possessing two different activities: an
exoribonuclease (ExoN) activity acting on both ssRNA and dsRNA in a 3′
to 5′ direction, and an N7-guanine methyltransferase activity (N7MTase) [21,22]. The activity of N7-MTase adds the N7-methyl guano
sine cap during mRNA cap synthesis that is necessary for nsp16, acti
vated by nsp10, to facilitate 2′ -O-ribose methylation of the viral mRNA
cap [23,24]. 2′ -O-Methylation is critical for CoV RNA to avoid host
recognition [25,26]. 2′ -O-Methylation is further discussed below. ExoN
activity has been suggested to be important for CoV replication and
transcription, as well as for RNA proofreading during its replication.
Using human CoV 229E and CoV murine hepatitis virus (MHV) respec
tively, Minskaia et al. (2006) and Eckerle et al. (2007) demonstrated
that ExoN active-site mutants possess defects in viral RNA synthesis
[22,27]. Eckerle et al. (2007) additionally demonstrated that ExoN
active-site mutants exhibit reduced replication fidelity [27]. Although
there are no reports as of yet revealing drugs that target guanine-N7
methyltransferase (ExoN) of SARS-CoV or MERS-CoV, given that ExoN is
important in coronaviruses for viral RNA synthesis and replication fi
delity as well as for avoiding recognition of CoV RNA by the host, we
assert it is to be a promising drug target (Fig. 2).
(4) nonstructural uridylate-specific endoribonuclease (NendoU)
Nsp-15. NendoU activity is found in the N-terminal domain. This active
site has been shown in MERS-CoV and SARS-CoV and is suggested to be a
genetic marker common to coronaviruses. MERS-CoV Nsp16 appears to
display unique features compared to its homologs. Nsp7/Nsp8 displays a
higher binding affinity for Nsp15, also affecting enzymatic activity.
Nsp15 from SARS-CoV appears to be an inhibitor of mitochondrial
antiviral signaling adaptor, inducing apoptosis. Nsp15 activity is stim
ulated by manganese ions (Mn2+) and the enzymes generate 2′ -3′ cyclic
phosphate ends [28]. Nsp15 functions as a homohexamer, although the
enzyme has some activity as a monomer [29]. The structures of MERSNsp15 and SARS-Nsp15 have been superimposed showing high homol
ogy [30]. Previous studies established that Nsp15 from both SARS-CoV
and MHV can be stimulated by Mn2+ [31]. The spatial arrangements
revealed that residues S290 and Y339 in MERS-Nsp15 correspond to
residues S293 and Y342 in SARS-Nsp15, which are postulated to interact
with the substrate and confer uridylate specificity [31], suggesting that
there is conserved recognition for uridylate [30,32,33].
(5) 2′-O-methyltransferase (2′-O-MT). Following the addition of
the N7-methyl guanosine cap, nsp16, activated by nsp10, mediates
mRNA cap 2′ -O-ribose methylation to the 5′ -cap structure of viral
mRNAs. This has been shown in SARS-CoV and MERS-CoV and shown to
be universal to coronaviruses [34,35]. 2′ -O-Methylation is important for
the host immune system to discern self RNA from non-self RNA. Thus,
through 2′ -O-methylation of viral RNA, coronaviruses can subvert host

innate immune responses by avoiding host recognition of their RNA
[35]. Menachery et al. (2014) have demonstrated the requirement of 2′ O-methyltransferase (2′ -O-MT) activity for SARS-CoV pathogenesis by
characterizing deficient strain to have reduced viral titers and viral
replication in-vitro and in-vivo (less weight loss and reduced breathing
dysfunction in mice) [35]. Similarly, the importance of nsp16 and thus
the activity of 2′ -O-methyltransferase (2′ -O-MT), has also been shown
for MERS-CoV pathogenesis. Menachery et al. (2017) introduced mu
tations in the MERS-CoV NSP16 conserved KDKE motif, which resulted
in significant attenuation of the viral load relative to the controls both invitro and in-vivo [34]. Despite there being no publication to date de
tailing drugs that target 2′ -O-Methyltransferase to treat SARS-CoV or
MERS-CoV, we are interested in 2′ -O-MT as a potential drug target
because of its role in avoiding recognition of CoV RNA by the host and its
importance for SARS-CoV and MERS-CoV pathogenesis (Fig. 2).
(6) viral helicase. Helicase is essential to viral genome replication
and is therefore a potential target for antiviral drug development. Virusencoded RNA helicases have important roles during viral life cycles for
folding and replication of viral RNA [36]. As such, Nsp13 possesses
NTPase and RNA helicases to facilitate hydrolysis of NTPs and unwind
RNA (Fig. 2). In one study, it was demonstrated that myricetin and
scutellarein are strong inhibitors of SARS-CoV helicase protein by
affecting its ATPase activity [37]. Helicase is a multi-functional protein
with a zinc-binding domain in the N-terminus displaying RNA and DNA
duplex-unwinding activities with 5′ to 3′ polarity. The activity of heli
case is dependent on magnesium (Mg2+). As such, bismuth salts have
been shown to inhibit NTPase and RNA helicase activities of SARS-CoV2 nsp13 [9,38]. Sequence annotation by Ivanov et al have shown that
SARS-CoV nsp13 is divided into three domains: (A) an N-terminal Zn(II)
binding domain and (B) a hinge domain, and (C) a helicase domain
[28,36]. Little is known of the viral nsp-12 activity, but activity occurs
on two domains, on the N-terminal subunit NiRAN, and motif BN on the
C-terminus. These sites have been shown in SARS-CoV and are suggested
to apply to coronaviruses in general [39,40].
(7) RNA-directed RNA polymerase (RdRP). RDRP plays a critical
RNA replication in RNA viruses due to its involvement in catalyzing
template synthesis of polynucleotides in the 5′ -3′ direction. Further,
RdRP is essential for the initiation of RNA replication in the host cell, a
key step in the RNA viruses infection cycle [41,42]. Chien et al. (2020)
have demonstrated the importance of RdRP activity for SARS-CoV
pathogenesis [43]. They showed that without RdRP, there is a com
plete disruption of SARS-CoV -RNA replication and viral growth halted
(Fig. 2). Additionally, these authors also suggested that the hepatitis C
drug EPCLUSA (Sofosbuvir/Velpatasvir) would target the active site of
RdRP to inhibit coronaviruses [44]. RdRP is an established drug target
for the treatment of SARS-CoV due to its role in viral RNA replication
and its importance for SARS-CoV pathogenesis RdRP is of particular
interest as a drug target.
3. Results and discussion
Following in-silico HTVS, molecular modeling, MDS, and utilizing
resources from the literature, we identified a series of potential lead
molecules from the repurposable drug libraries against proteins that are
critical for the ability of SARS-CoV-2 to infect and reproduce within the
host cell (Tables 1–7). Additionally, all of the simulated hit-target
complexes were found to be strongly interacting and exhibited highly
stable binding indicating the potential of being potent inhibitors of key
SARS-CoV-2 enzymes and therefore promising candidates or leads for
further development. Outputs from these analyses are presented in ta
bles (Tables 1–7) and graphically (Top three interaction maps Supple
mentary Fig. 1,3,5,7,9,11&13), and are discussed in the following
sections.
2′-O-methyltransferase (2′-O-MT) hits (Table 1). Maltotetraose is
an oligosaccharide of four units of alpha-D-glucopyranose linked by
alpha-(1–4) bonds. This is a sugar variant of a substance that is found to
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Table 1
2′ -O-methyltransferase (2′ -O-MT) hits.
Dock
ID

Compound name

Indicated target

Glide
Energy

DockScore

LipophilicEvdW

HBond

Electro

ExposPenal

RotPenal

A

Maltotetraose

− 58.44

− 11.31

− 1.54

− 6.96

− 2

0.09

0.1

B

Natural Crocin
and/or Crocetin

− 53.89

− 10.36

− 1.68

− 6.05

− 1.84

0.14

0.07

C
D

Paclitaxel
NADH dianion

− 70.51
− 61.72

− 8.7
− 8.55

− 1.24
− 1.56

− 5.03
− 5.69

− 2
− 2

0.38
0.74

0.17
0.14

E

Iohexol

− 67.38

− 6.04

− 2.87

− 2.84

− 1.37

0.8

0.19

F

Heparin

Substances that inhibit the growth or reproduction
of BACTERIA
for treating neurodegenerative disorders of the
central nervous system, e.g. nootropic agents,
cognition enhancers, drugs for treating Alzheimer’s
disease or other forms of dementia
inhibits the disassembly of microtubules
Dianion of NADH arising from deprotonation of the
two diphosphate OH groups; major species at pH
7.3.
MRI contrasting agent/ histone acetyltransferase
KAT2A (human)
Anticoagulant

− 86.41

− 12

− 4.02

− 12-

4.02

1.1

0.07

Table 2
RNA-dependent RNA polymerase hits.
Dock
ID

Compound
name

Normal target

Glide
Energy

DockScore

LipophilicEvdW

HBond

Electro

ExposPenal

RotPenal

A
B

Lactulose
Framycetin/
Paromomycin
Amikacin/
Arbekacin
Bekanamycin
Lividomycin A
Lapatinib
Ditosylate

Laxative & portal-systemic encephalopathy (PSE)
16S ribosomal RNA

− 67.99
− 66.49

− 15.22
− 14.87

− 2.9
− 1.56

− 11.26
− 6.87

− 2
− 2

0.11
0.22

0.19
0.11

16S ribosomal RNA

− 73.4

− 14.06

− 1.87

− 10.24

− 2

0.19

0.11

Not Available
Not Available
Blocks phosphorylation of the epidermal growth
factor receptor (EGFR), ErbB2, and the Erk-1 and-2
and AKT kinases; it also inhibits cyclin D protein
levels in human tumor cell lines and xenografts.

− 63.88
− 64.68
− 51.39

− 14.69
− 14.6
− 12.03

− 2.31
− 2.22
− 1.31

− 6.6
− 6.56
− 5.48

− 2
− 2
− 2

0.2
0.18
0.01

0.06
0.11
0.11

C
D
E
F

Table 3
Uridylate-specific endoribonuclease (NendoU) Hits.
Dock
ID

Compound name

Normal target

Glide
Energy

DockScore

LipophilicEvdW

HBond

Electro

ExposPenal

RotPenal

A

Daidzin

− 68.65

− 14.56

− 1.9

− 6.32

− 2

0.05

0.11

Ba

SCHEMBL24383,
ZINC8143723

− 72.09

− 14.52

− 1.87

− 6.28

− 2

0.03

0.11

Bb
C

Metrizamide
Haloperidol
Glucuronide
4-Hydroxyphenytoin
glucuronide
acetaminophen O-β-Dglucosiduronate

Aldehyde dehydrogenase, mitochondrial
(human)
Active principle of Strychnos potatorum Linn.
Seed extracts. Known antiallergic,
antianaphylactic and mast cell stabilization
activity
Resorbable, non-ionic contrast medium.
Anti-depressant

− 71.41
− 71.81

− 14.26
− 13.48

− 1.78
− 2.61

− 6.32
− 9.12

− 2
− 2

0.23
0.19

0.11
0.06

Phenytoin metabolite by liver UDPglucuronosyltransferase.
A β-D-glucosiduronate that is the conjugate
base of acetaminophen O-β-D-glucosiduronic
acid
Heat-labile enterotoxin B chain

− 74.49

− 13.5

− 1.87

− 7

− 2

0.18

0.19

− 70.28

− 14.07

− 1.51

− 6.27

− 2

0.1

0.11

− 71.44

− 14.06

− 1.87

− 5.82

− 2

0.02

0.11

D
E
F

p-Aminophenyl-alphaD-Galactopyranoside

inhibit the growth and reproduction of bacteria [45,46]. Ligand inter
action maps of the top 3 hits are shown in ‘Supplementary Fig. 1.’ The
20 ns long MD simulation revealed the interaction to be a very strong
one validating the pipeline (Supplementary Fig. 2). Crocin/Crocetin are
the major bioactive ingredients of saffron. There have been several
studies that have shown the various efficacies of these drugs, including
as neurotropic and chemotherapeutic agents [47,48]. Crocin/Crocetin
are popular agents to be tested in clinical settings due to their antioxidative properties [49]. Paclitaxel is a diterpene alkaloid natural
product and belongs to a family of drugs that target tubulin leading to an
abnormality of the mitotic spindle assembly, chromosome segregation,
and consequently defects of cell division [50]. Paclitaxel is one of the
most widely used anticancer drugs for the treatment of various cancers
[51]. Other studies have shown that low doses of paclitaxel show

promise in treating some non-cancer diseases including renal and he
patic fibrosis and artery restenosis [52–54]. NADH dianion is a species of
NADH that arises from the deprotonation of the two diphosphates OH
groups. Iohexol is a compound most well-known as a nonionic, watersoluble radiographic contrast medium used especially for renal disease
determination. This compound is absorbed from the cerebrospinal fluid
into the bloodstream and is eliminated by renal excretion. Heparin is a
very interesting hit as it has been reported in multiple studies to increase
the likelihood of survival of terminal COVID-19 patients [55,56] by a
mechanism that is not well understood but likely involves heparin’s
activity of reducing hypoxia as well via inhibiting the cytokine storm
[57]. There is a minor report suggesting that hepcidin hormone mimics
the spike protein of SARS-CoV2, [58], and heparin is known to interfere
with hepcidin [59]. This suggests that heparin’s anti-COVID activity
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Table 4
Guanine-N7 methyltransferase (ExoN) Hits.
Dock
ID

Compound name

Normal target

Glide
Energy

DockScore

LipophilicEvdW

HBond

Electro

ExposPenal

RotPenal

A

Diosmin

− 68.66

− 13.26

− 1.66

− 6.01

− 2

0.11

0.11

B
C

− 71.34
− 72.69

− 13.24
− 13.23

− 2.01
− 1.77

− 5.57
− 6.22

− 2
− 2

0.05
0.48

0.11
0.11

Carboxypeptidase A1

− 68.77

− 13.17

− 1.65

− 6.08

− 2

0.28

0.11

E

Hidrosmin
N-Desmethyl-4-hydroxy
tamoxifen beta-Dglucuronide (E/Z Mixture)
Octane-1,3,5,7tetracarboxylic acid
Bempedoic acid

Diosmin, a flavone that can be found in
the plant Teucrium gnaphalodes. Is an
agonist at the human aryl hydrocarbon
receptor
Capillary stabilizing agent
N/A

− 71.39

− 13.15

− 2.14

− 5.48

− 2

0.22

0.08

F

Bisindolylmaleimide IX

Metabolic activation affords ETC-1002CoA, the pharmacologically active
metabolite. ATP lyase (a.k.a. ATP
synthase) plays an important part of
cholesterol synthesis
PKC Inhibitor, Potential anti-cancer
activity

− 50.6

− 7.8

− 4.5

− 2.7

− 0.7

0.0

0.3

D

Table 5
Helicase (HEL) Hits.
Dock
ID

Compound
name

Normal target

Glide
Energy

DockScore

LipophilicEvdW

HBond

Electro

ExposPenal

RotPenal

A

Inosine

− 72.87

− 13.05

− 1.76

− 6.23

− 2

0.66

0.11

B
C
D
E

5-F-UMP
Fenoterol
Didanosine
Doxifluridine

Neurorestorative, anti-inflammatory,
immunomodulatory, and cardioprotective effects.
Bacterial Thymidylate synthase
Agonist to Beta-2 adrenergic receptor
Anti-HIV
Not Available/Anti-cancer

2
2
2
2

0.13
0.13
0.66
0.09

0.08
0.08
0.11
0.13

−
−
−
−

57.22
57.22
72.87
68.72

−
−
−
−

12.94
12.94
12.94
12.9

−
−
−
−

1.79
1.79
1.76
1.88

−
−
−
−

6.68
6.68
6.12
5.81

−
−
−
−

Table 6
Papain-like proteinase (PLpro) Hits.
Dock
ID

Compound name

Normal target

Glide
Energy

DockScore

LipophilicEvdW

HBond

Electro

ExposPenal

RotPenal

A
B

Troxerutin
4-O-(4,6-Dideoxy-4-{[4,5,6-trihydroxy-3(hydroxymethyl)cyclohex-2-en-1-yl]amino}-BetaD-lyxo-hexopyranosyl)-alpha-D-erythrohexopyranose
4,6-Dideoxy-4-{[4,5,6-trihydroxy-3(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alphaD-lyxo-hexopyranosyl-(1->4)-alpha-D-threohexopyranosyl-(1->6)-alpha-L-threo-hexopyranose
Hyaluronic acid
Monoxerutin
Anastrozole

Not known
Pancreatic alphaamylase
(DB03495)

− 73.57
− 61.8

− 13.5
− 13.79

− 1.62
− 1.53

− 2
− 2

− 7.17
− 5.92

0.19
0.05

0.09
0.11

Pancreatic alphaamylase
(DB02889)

− 75.87

− 13.3

− 1.72

− 2

− 5.36

0.25

0.11

Supplement
Not known
Non-steroidal
aromatase
inhibitor (AI)

− 64.36
− 64.68
− 61.81

− 13.24
− 14.6
− 14.48

− 2.04
− 13.92
− 12.65

− 2
− 2
− 2

− 5.21
− 6.56
− 2

0.4
0.02
0.19

0.11
0.11
0.06

C

D
E
F

may present a multifaceted therapy option. MMGBSA re-ranking
brought this molecule to the bottom despite a high glide energy score
due to penalties exacted due to extra-active site exposure of the bulky
compound.
RNA-directed RNA polymerase (RdRP) hits (Table 2). The SARSCoV-2 RdRP is predicted to bind tightly to aminoglycosides. Ligand
interaction maps of the top 3 hits are shown in ‘Supplementary Fig. 3.’
Drug screening reveals many hits from this class of antibiotics including
Framycetin, Paromomycin, Amikacin, Arbekacin, Bekanamycin, & Liv
idomycin A. While aminoglycosides have a binding affinity for RNA and
have been reported to inhibit binding of RdRP to the decoding loop in
case of influenza [60] the complementary RNA binding site of RdRP has
also been reported to be susceptible to aminoglycosides such as
neomycin B which targets HCV RdRP [61]. Interestingly, the highestscoring among the aminoglycoside hits is Paromomycin which is an
antiparasitic used to treat amoebiasis, visceral leishmaniasis, and

cryptosporidiosis in immunocompromised patients. With the potential
to treat pulmonary tuberculosis as well, the range of indications of this
drug is indeed very wide and if found effective against COVID-19, it
could prove to be a valuable addition to the arsenal of combination
therapies. The Paromomycin RdRP complex was simulated for 20 ns and
the interaction was highly stable throughout the simulation validating
the pipeline for RdRP (Supplementary Fig. 4).
Lactulose is a synthetic disaccharide of galactose and fructose which
can be produced by the isomerization of lactose. This compound has
been used for treating bacterial infections, constipation, and cancer. An
important note on lactulose is that it is not hydrolyzed by mammalian
enzymes, therefore, ingested lactulose passes through the stomach and
small intestine without degradation [62]. Framycetin is an aminoglyco
side antibiotic isolated from Streptomyces lavendula that shows broadspectrum antibacterial activity. This drug has been used as a therapeu
tic against a variety of cancers [63,64]. Amikacin is an aminoglycoside
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Table 7
Main proteinase (3CLpro)Hits.
Dock
ID

Compound name

Normal target

Glide
Energy

A
B
C
D
E
F
G
H

XAV-939
Crocin
Iopromide
Troxerutin
Isoquercetin
Danoprevir
Cefoperazone
Nevirapine

−
−
−
−
−
−
−
−

I
J

Pentostatin
Cladribine

K

Bisindolylmaleimide
IX

Not known; Anti-cancer
Arthritis
non-ionic X-ray contrast agent
Chronic Venous Insufficiency
Anti-cancer
Inhibitor of the HCV NS3/4A protease
Cephalosporin; antibacterial
Non-nucleoside reverse transcriptase
inhibitor (NNRTI)
Adenosine deaminase; anti-cancer
Synthetic purine nucleoside that acts as an
antineoplastic agent
PKC Inhibitor, Potential anti-cancer activity

71.17
63.96
77.95
64.53
73.56
66.83
79.52
63.17

DockScore
−
−
−
−
−
−
−
−

12.66
11.56
11.07
10.69
10.31
10.03
7.8
7.79

LipophilicEvdW
−
−
−
−
−
−
−
−

5.74
3.24
5.34
4.69
4.89
4.73
3.14
3.31

HBond
−
−
−
−
−
−
−
−

5.98
6.68
4.64
4.29
4.42
4.01
4.22
3.25

Electro
−
−
−
−
−
−
−
−

ExposPenal

RotPenal

1.46
2
1.63
1.42
1.71
1.44
1.67
1.09

0.37
0.23
0.39
0
0.54
0.04
0.7
0.11

0.15
0.14
0.15
0.11
0.17
0.11
0.19
0.14

− 81.01
− 78.93

− 7.12
− 6.86

− 3.78
− 5.19

− 3.74
− 1.48

− 2
− 1.09

2.09
0.85

0.19
0.19

− 56.2

− 5.9

− 5.1

− 0.6

− 0.6

0.1

0.3

antibiotic that is on the WHO list of essential medicines. It is a pro
karyotic translation inhibitor that binds to the 16S ribosomal subunit.
Bekanamycin is another aminoglycoside that inhibits prokaryotic trans
lation by binding to the highly conserved A site of 16S rRNA in the 30S
ribosomal subunit. This compound has the lowest antibacterial activity
of the aminoglycosides in clinical use and manifests a moderate level of
toxicity, therefore, it is no longer used as a first-line antibiotic[65].
Lividomycin A is an aminoglycoside that shows antibiotic activity against
several of the Gram+/− bacteria by inhibiting protein synthesis [66].
Lapatinib ditosylate is the salt of Lapatinib, a synthetic quinazoline that
blocks the phosphorylation of various epidermal growth factor receptors
and inhibits cyclin D protein levels in human tumor xenografts and cell
lines [67,68].
Uridylate-specific endoribonuclease (NendoU) Hits (Table 3).
Ligand interaction maps of the top three hits are shown in ‘Supple
mentary Fig. 5.’ Daidzin is an isoflavone natural product found in
several Legumimosae such as the Japanese Kudzu root and is the 7-Oglucoside of the isoflavone daidzein. It is shown to have anticancer and
antiallergenic activities [69]. Daidzein and Haloperidol have been
identified in multiple virtual screenings [70,71]. MD Simulation of the
Daidzin-NendoU complex for 20 ns revealed a stable and energetically
favorable interaction and validated the pipeline for the NendoU virtual
screening (Supplementary Fig. 6). SCHEMBL24383 (Active principle of
Strychnos potatorum Linn. seed extracts) has been extensively used to
combat respiratory diseases including asthma, chronic obstructive pul
monary disease (COPD), and bronchitis. Interestingly, given its pre
dicted anti-COVID-19 activity, it may result in a dual therapeutic
potential drug. Metrizamide is a non-ionic iodine-based radiocontrast
agent that is widely used in lumbar myelography [72]. Haloperidol
glucuronide is a metabolite of the commonly prescribed antipsychotic
drug on the WHO’s list of Essential Medicines. Haloperidol is used in the
treatment of schizophrenia, mania in bipolar, delirium, and other
neurological diseases [73,74] and is on the WHO’s List of Essential
Medicines. 4-Hydroxy phenytoin glucuronide is a metabolite of the widely
used antiepileptic phenytoin. The adverse effects of phenytoin can range
from moderate diseases including gingival hyperplasia to severe more
effects including toxic epidermal necrolysis and teratogenic effects [75].
Similarly, acetaminophen O-β-D-glucose iduronate is a metabolite of
acetaminophen generated in the liver by UDP-glucuronyltransferase. It
is highly water-soluble and is excreted through the kidneys. Acetamin
ophen was recommended by WHO in the case of COVID-19 due to a
concern over ibuprofen being an ACE2 inhibitor that might increase
viral entry [76]. The advisory was subsequently revised to state that
both medications are appropriate [77]. A metabolite of acetaminophen
could prove to be an added advantage of already being used as a drug. pAminophenyl-alpha-D-galactopyranoside is an experimental phenolic
glycoside that competitively binds to heat-labile enterotoxin B pen
tamers by mimicking host cell receptors (intracellular adenylyl cyclase)

[78].
Guanine-N7 methyltransferase (ExoN) Hits (Table 4). Ligand
interaction maps of the top 3 hits are shown in ‘Supplementary Fig. 7.’
Diosmin is a flavone glycoside that is mostly found in citrus fruits. It is a
non-prescribed dietary supplement that is primarily used for venous
diseases, although there is limited clinical data to support its efficacy.
Common adverse effects include mild gastrointestinal disturbances and
cardiac arrhythmias [79]. Interestingly other studies have reported
diosmin to be a coronavirus main protease inhibitor. MD Simulations for
20 ns with Diosmin-ExoN complex revealed a very strong binding
establishing the target specificity of Diosmin and validated the screening
pipeline with ExoN (Supplementary Fig. 8). Hidrosmin is a synthetic
bioflavonoid that is used to treat chronic venous insufficiency of the
lower limbs [80]. A crude preparation of Diosmin and Hidrosmin has
been determined to be effective against COVID-19 [81]. N-Desmethyl-4hydroxy tamoxifen beta-D-glucuronide (E/Z Mixture) has also been
identified as a strong binding ligand. Tamoxifen has also been proposed
as an anti-COVID-19 drug as it can induce autophagy associated with the
unfolded protein response to kill infected cells and thus contain the virus
[82]. Octane-1,3,5,7-tetracarboxylic acid B belongs to the class of zinc
ion binding compounds that target Carboxypeptidase A1.
Bempedoic acid is a prodrug that is converted to its active form in the
liver. It is an FDA approved treatment for hypercholesterolemia and has
few adverse effects. This compound inhibits adenosine triphosphate
citrate lyase, an enzyme within the cholesterol biosynthesis pathway
[83]. Bisindolylmaleimide IX (BIM IX) a was strongly bound to ExoN
active site for a 100 ns simulation (Figs. 4 & 5(B)) and the stable complex
had a tight binding with the whole molecule involved in interactions
with 3CLpro active site side-chain amino acid residues (Figs. 4(B) & 5
(B)).
Helicase (HEL) Hits (Table 5). Ligand interaction maps of the top 3
hits are shown in ‘Supplementary Fig. 9.’ The FDA approved drug
ivermectin recently showed significant anti- SARS-CoV-2 antiviral ac
tivity, suggesting its therapeutic potential [84]. While the target of
ivermectin in SARS-CoV-2 is yet to be confirmed, it has been reported
that its antiviral activity in the case of flaviviruses, particularly the
Australian Kunjin virus (West Nile virus variant) [85] is based on tar
geting viral helicases. While our screening did not show ivermectin as a
top helicase inhibitor, its binding activity established viral helicase as an
important target in SARS-CoV-2. We found several small-molecule
compounds including inosine, 5-F-UMP, fenoterol, didanosine, and
doxifluridine as potential helicase inhibitors. While Inosine, 5-F-UMP,
and fenoterol have a high affinity towards the ATP-Nucleic acid inter
face, our top target against Helicase is inosine. Inosine is a nucleoside
commonly found in tRNAs and is essential for proper translation of the
genetic code in wobble base pairs. It has been tried in various clinical
settings, most notably in multiple sclerosis [86]. MD Simulations for
20 ns with the Helicase-Inosine docked complex revealed a very strong
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Fig. 4. Results of a 100 ns MD simulation. (A) Root mean square deviations difference between guanine-N7 methyltransferase (ExoN) and bound ligand BIM IX (<4
Å). Graph obtained for RMSF value of ligand (purple line) from the protein back bone (green line). The ligand was tightly bound to the active site throughout the
simulation. The complex progressed towards a more stable state during the simulation. This suggests two binding conformers of same ligand within the binding site.
(B) Schematic 2D representation of bound ligand interactions of BIM IX throughout the simulation. (C) Root mean square fluctuation between the binding site of
target protein and interacting ligand. (D) Critical protein ligand contacts of amino acid side chain residues with the interaction properties. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)

binding establishing the target specificity of Inosine and validated the
screening pipeline with HEL (Supplementary Fig. 10). 5-F-UMP is a
pyrimidine ribonucleoside 5′ -monophosphate having 5-fluorouracil as
the pyrimidine component. It shows antineoplastic activity by being
inorporated in RNA and it inhibits RNA processing, thereby inhibiting
cell growth. Fenoterol is a β adrenoreceptor agonist that is used as an
inhaled bronchodilator asthma medication [87]. Didanosine is particu
larly interesting as it is a reverse transcriptase (HIV) inhibitor [88]. Also,
Didanosine has been profiled as a beneficial drug in the case of the
COVID-19 type of lung fibrosis by matching single-cell RNA sequencing
data [89]. Inhibition of inosine-5′ -monophosphate dehydrogenase
(IMPDH) has been shown to control SARS-CoV-2 replication [90], which
could be due to inosine accumulation. Didanosine is also a medication
used to slow the progress of HIV/AIDS and is a nucleoside analog of
adenosine. There are several common adverse effects associated with
this medication including diarrhea, vomiting, and peripheral neuropa
thy [91]. Fenoterol has already been recommended to reduce severe
pulmonary symptoms of COVID-19 patients [92]. Doxifluridine has been
suggested as a possible SARS-CoV-2 inhibitor based on similarities with
active antivirals already tested by artificial intelligence [93]. Doxi
fluridine is a nucleoside analog prodrug that interferes with RNA tran
scription by competing with uridine triphosphate for incorporation into
the RNA strand. It is used as a cytostatic agent in chemotherapy in
several countries in Asia [94].
Papain-like proteinase (PLpro) Hits (Table 6). The ligand inter
action maps of the top 3 hits are shown in ‘Supplementary Fig. 11.’
Troxerutin is a naturally occurring flavonoid that has been reported to
show promise as a vasoprotective agent by improving hepatic homeo
stasis [95]. There have been many in silico drug screening efforts with
the coronavirus Main Protease that have predicted troxerutin as a po
tential inhibitor of 3Clpro [96]. Also, the famous ‘Chai-Ling decoction’ a
Chinese medicine herbal formulation with reported protection from
SARS, MERS, and now COVID-19 has troxerutin as a major component
[97,98]. MD Simulations for 20 ns with troxerutin-PLpro docked com
plex revealed a very strong binding establishing the target specificity of
troxerutin and validated the screening pipeline with PLpro

(Supplementary Fig. 12). The identified hit 4-O-(4,6-dideoxy-4-{[4,5,6trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-beta-D-lyxohexopyranosyl)-alpha-D-erythro-hexopyranose is an aminocyclitol
glycoside, as well as 4,6-dideoxy-4-{[4,5,6-trihydroxy-3-(hydrox
ymethyl)cyclohex-2-en-1-yl]amino}-aapha-D-lyxo-hexopyranosyl-(1>4)-alpha-D-threo-hexopyranosyl-(1->6)-alpha-L-threo-hexopyranose
have been shown to target pancreatic alpha-amylase [99]. Both of these
compounds belong to the class of aminocyclitol glycosides similar to
streptomycin. This class of compounds has been used previously to
target the RNA metabolism of viruses [100]. Hyaluronic acid is a nonsulfated glycosaminoglycan (GAG) and is composed of repeating poly
meric disaccharides of D-glucuronic acid and N-acetyl-D-glucosamine
linked by a glucuonidic β (1 → 3) bond [101]. It is a key molecule
involved in skin moisture that can retain water. Monoxerutin is another
flavonoid which has been patented to be used against Hepatitis C [102].
Anastrozole is an aromatase inhibitor approved by the FDA to treat
postmenopausal women diagnosed with hormone receptor-positive
breast cancer at advanced-stage or early-stage after surgery [103,104].
Main proteinase (3CLpro) Hits (Table 7). Ligand interaction maps
of the top 3 hits are shown in ‘Supplementary Fig. 13.’ XAV-939 is a betacatenin signaling inhibitor that has been shown to have promise in
treating prostate cancer [105]. XAV-939 is also an effective inhibitor of
PARP and Wnt pathway. PARPs enhance IFNγ production and can halt
viral infections [106,107]. Thus, a dual-mode of action is expected of
XAV-939 if it is found to inhibit the main protease as well. MD Simu
lation of XAV-939-3CLpro docked complex for 100 ns revealed a stable
and energetically favorable interaction and validated the pipeline for the
3CLpro virtual screening (Supplementary Fig. 14). Crocin is a carotenoid
diester that is responsible for the color of saffron and is popularly used in
India as a treatment for arthritis and psychological disorders [108].
Loperamide is used to treat gastrointestinal symptoms including diarrhea
with few side effects and is on the WHO’s List of Essential Medicines.
Isoquercetin is a flavonoid natural product that can be isolated from
various plant species and has shown promise as an anti-cancer agent
[109]. Danoprevir is a 15-membered ring macrocyclic peptidomimetic
inhibitor of the hepatitis C protease NS3/4A [110]. Other virtual drug
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screenings have reported danoprevir as a possible coronavirus main
protease inhibitor [111]. In clinical trials, danoprevir had a positive
effect on recovery and faster discharge of COVID-19 patients [112].
Cefoperazone is a cephalosporin antibiotic. It is one of the few cephalo
sporin antibiotics effective in treating Pseudomonas bacterial infections
[113]. In China, most of the treatment regimens reported using cefo
perazone to prevent secondary infections in COVID-19 patients
[114,115]. Nevirapine is a non-nucleoside reverse-transcriptase inhibitor
[116]. This compound is FDA approved for use in adult patients infected
with HIV-1. Nevirapine has also been revealed in various in-silico drug
screening with the main protease [117,118]. Pentostatin is a purine
analog that is widely used as a treatment for hairy cell leukemia [119].
Similar to pentostatin, cladribine is also a therapy for hairy cell leukemia.
And also like nevirapine, cladribine has been predicted to block main
protease 3CLpro in many reports [118,120]. Bisindolylmaleimide IX a
PKC inhibitor, strongly bound to 3CLpro for a 100 ns simulation (Figs. 3
& 5(A)), and the stable complex exhibited a tight binding with the whole
molecule involved in interactions with 3CLpro active site side-chain
amino acid residues (Figs. 3(B) & 5(A)).
In-vitro anti-SARS-CoV-2 testing of select drug compounds. All
compounds unless stated otherwise were procured from Selleck Chem
icals LLC (Houston, TX). As per screening results, Troxerutin (3CLpro &
PLpro) and BIM IX (3CLpro & Exon) had possible dual targets, while
other targets were shortlisted based on novelty and scores. Mild antiSARS-CoV-2 activity at higher concentrations; at 25 µM Amikacin
(7.2%), Troxerutin (2.8%), Paromomycin (2.3%%) & Haloperidol (9.8%
%) had non-translatable activity (Figs. 6 and 7). Lactulose & Iopromide
had no observed inhibitory activity, which could be due to low intra
cellular accumulation as Lactulose is anti-diarrhea and Iopromide is an
MRI contrast agent. This supports the predicted interaction and MOA
and can be used to improve or screen more members from the same
chemotypes and similar pharmacophore. Lactulose (Anti-Diarrhea) and
Iopromide (MRI contrast) both showed no activity at the concentration
range tested. This could be due to a lack of cell permeability as both are
not used for intracellular functions. An inhibitory concentration (IC50)
was estimated by curve fitting over linear regression of Log10 drug
concentrations vs. normalized data (percentage, Table 8). The IC50 was
plotted on the variable slope of the drug responses (Figs. 6 and 7).
Bisindolylmaleimide derivatives are widely used as inhibitors of
protein kinase C (PKC) isoforms. Bisindolylmaleimide IX (BIM IX), also
known as Ro 31-8220, is an advanced investigational molecule and one
of the most commonly used PKC inhibitor standards [121]. BIM IX is an
imidothio carbamic ester, as well as a bis-indole maleimide. Several
reported pharmacological effects of BIM IX; stimulation of c-Jun-N-ter
minal kinase (JNK) expression, an activator of p38 MAPK through
phosphorylation; activation of glycogen synthase activity in adipocytes,
among other effects [122–124]. BIM IX shows potent inhibition of PKC

α, PKC βI, PKC βII, PKC γ, and PKC ε [125]. BIM IX also inhibits MSK1,

MAPKAPK1, RSK, GSK3β, and S6K1 with a potency similar to that for
PKC [125]. BIM IX significantly decreases apoE secretion from primary
human macrophages by inhibiting vesicular transport of apoE to the
plasma membrane without significantly affecting apoE mRNA or apoE
protein levels [125]. Bim IX has been extensively studied in several
animals and human tissue types showing a safe profile [126–128]. In the
context of SARS CoV2, the anti-inflammatory and anti-bronchitis profile
of this molecule may prove to be an additional therapeutic advantage
[127]. While the effect of PKC inhibition on this particular virus is not
known, but the SARS-CoV pathogenesis profile is known to be greatly
dependent on PKC [129,130].
Validation of 3CLpro target through enzyme inhibition assay.
To characterize the mechanistic aspects of BIM IX activity, biochemical
studies of the 3CLpro enzyme-inhibitor complex were performed. We
used a peptide substrate with a C-terminal 7-amino-4-methyl-coumarin
(AMC) with a fluorogenic reporter group to perform kinetic assays of
3CLpro inhibition. BIM IX and Haloperidol were tested at four concen
trations and the rate of substrate cleavage was recorded at different time
points (Fig. 8). Haloperidol had a very mild activity, while BIM IX had
significant activity. Finally, BIM IX concentrations were varied relative
to a fixed concentration of the peptide substrate and monitored over
time. Inhibition was observed with an IC50 value of 113.7 ± 5.2 µM
(Fig. 9).
4. Conclusion
The rapid spread of SARS-CoV-2 continues to create havoc in health
systems and economies, affected every nation around the world. As this
is a novel coronavirus, vaccines are being developed at an unprece
dented pace and we must also resort to the rapid development of ther
apeutics for COVID-19. There has been an international focus on the
potential efficacy of repurposable drug candidates including remdesivir
and hydroxychloroquine, among others. With each controlled clinical
study that comes out, it becomes more evident that nations were too
quick to push certain compounds, consequently reducing the supply to
patients who needed them to treat already indicated diseases [131].
There is a possibility that these compounds may still have a place in the
clinical realm as a treatment for COVID-19, but not as stand-alone
therapies as currently utilized. Until a SARS-CoV-2 specific compound
is developed and clinically approved, the best way is to find treatment
through a multifaceted approach of repurposing as well as developing
new drugs. This philosophy is at the forefront of our work, first by
screening approved compounds for repurposing potential, and by
identifying the best possible combinations providing a possible treat
ment for SARS-CoV-2.
In this context, we commenced a CADD through the HTVS approach

Fig. 5. Post simulation 3D interaction representation for BIM IX (Pink licorish). A) 3CLpro active site and B) ExoN active site). The active site is depicted as
translucent surface model covering binding side chain aminoacid recidues as thiner line labeled and colored individually. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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Fig 6. SARS CoV2 anti-viral entry assay. Synchronized infections were conducted for viral entry as described in Materials and Methods. Each curve shows a doseresponse to the indicated 8 drug compounds (Color-coded; key inset). The results are presented as the PFU formed in the presence of drug as a percentage of the PFU
formed and each plotted value is the mean with ± standard deviations of an experiment performed in triplicate.

Fig 7. SARS-CoV2 Anti-viral spread assay. Synchronized infections were conducted for a viral spread as described in Materials and Methods. Each curve shows a
dose-response to the indicated 8 drug compounds (Color-coded; key inset). The results are presented as the PFU formed in the presence of drug as a percentage of the
PFU formed and each plotted value is the mean with ± standard deviations of an experiment performed in triplicate.

using a large pool of world approved drug libraries to identify potential
drugs for immediate deployment (Fig. 1). Our in-silico studies have
shortlisted a series of repurposable drugs that can be utilized in clinical
trials. From our eight selected approved compounds that underwent invitro studies against SARS-CoV-2, we found two compounds with high
inhibitory activity. One of these was ivermectin, which showed

significant viral inhibition, confirming the results of a previous study
[84]. Like previous reports, our in-vitro studies found that ivermectin has
nonselective toxicity to the ATCC E6 Vero cells at ≤ 50 μM and 16.67 μM
based on the number of nuclei counted. This shows that high doses
(>16.67 μM) of ivermectin have high cytotoxicity as reported by other
groups [132,133], and this must be considered when preparing to use
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Table 8
Results of anti-SARS-CoV-2 testing. Note: ‘Very wide’ means some activity was observed at high concentrations too staggering to plot.
Test compound

IC50_Viral Entry blocking
assay (µM)

Percent inhibition at
50 µM (%)

IC-50_Viral Spread
assay (µM)

Percent inhibition at
50 µM (%)

Cytotoxicity (µM)

Predicted
Target(s)

*Bisindolylmaleimide
IX
Ivermectin

28.18

80

381.5

15

2.702

99

6.015

46

Nontoxic within tested
conc. range
Toxic above 50

*Haloperidol

(Very wide)

10

(Very wide)

03

Troxerutin

(Very wide)

11

(Very wide)

03

Amikacin hydrate

(Very wide)

08

(Very wide)

03

3CLpro and
ExoN
Probably
Helicase
NendoU and
3CLpro
3CLpro and
PLpro
RdRP

Paromomycin

~99.86

05

(Very wide)

02

Lactulose

nil

01

nil

03

Iopromide

nil

02

nil

02

Non-toxic within tested
conc. range
Nontoxic within tested
conc. range
Nontoxic within tested
conc. range
Nontoxic within tested
conc. range
Nontoxic within tested
conc. range
Nontoxic within tested
conc. range

RdRP
RdRP
3CLpro

NT, Not tested
* Targets validated.
* Compounds with validated MOA through in-vitro assay.

Fig 8. Preliminary compound screening for 3CLpro inhibitors. Fluorescence-based biochemical activity assay for (A) BIM IX (B) Haloperidol and (C) Disulfiram (+ve
control) using the TVLQ-AMC probe substrate. Each point is the mean of compounds screened in duplicate (1–50 µM) or a DMSO control (0 µM) for n = 2 replicate
screens. Emission is normalized to 0 µM at 3 h to identify compounds with inhibitory activity toward 3CLpro.

toxicity screens for better drug repurposing screens. Overall, this is the
first study that showcases the possibility of using bisindolylmaleimide IX
specific derivatives and an urgent need to further evaluate their suit
ability to advance to clinical use to treat COVID-19.
5. Methods
Protein (Receptor) structures. The crystal structures of NSP3 (PDB
ID- 6 W02), NSP9(PDB ID- 6W4B), NSP15 (PDB ID- 6VWW) from SARS
CoV-2 were obtained from Protein Data Bank [134]. The crystal struc
tures of COVID-19 main protease (NSP5) in complex with Z44592329
(ID:5r83) were obtained from the Protein Structure Database of Europe
[135]. QHD43415 [9]: the I-TASSER models were obtained for NSP3
(QHD43415_3), NSP5 (QHD43415_5), NSP11(QHD43415_11), NSP12
(QHD43415_12), NSP13(QHD43415_13), and NSP14 (QHD43415_14)
[9].
Target Proteins (Receptors) preparation. Proteinpreparationwas
performed usingthe ProteinPreparation Wizard in Maestro [10]. All cocrystallized atoms including calcium and chlorine were deleted. Cocrystalized ligands within the active site were not deleted because
they were used for grid generation. All water with less than 3 hydrogen
bonds (Sample water orientation) with ‘non-waters’ i.e. receptor protein
or ligand were deleted. Each of the seven models developed was sub
jected to preparation by the Wizard in Maestro [10]. Each of the com
plexes was optimized with minimized hydrogens of altered species and
then minimized using the OPLS3e force field [10,136]. Further, the
models were subjected to MD simulation (MDS) after solvation in water

Fig 9. 3CLpro inhibition assay. Fluorescence-based biochemical activity assay
for BIM IX using the TVLQ-AMC probe substrate. All values are mean ± stan
dard deviation with n = 3 replicates.

this drug in COVID-19 clinical trials as its currently approved dosage is
very low (25 mg) [84]. The second compound with significant inhibitory
activity against in-vitro SARS-CoV-2 was bisindolylmaleimide IX.
Further, BIM IX specifically blocked 3CLpro in-vitro enzymatic assay
confirming the robustness of our in-silico prediction pipeline. Higher
activity in entry assays of 3CLpro inhibitors points to its high activity as
once it is expressed in sufficient amounts partial inhibition has a
diminished effect or viral replication. This is a critique for high
throughput screening assays (spread assay format) as they might miss
inhibitors for this target. The target-specific high throughput screenings
(both enzymetic and anti-viral) are needed to be designed with parallel
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and 0.15 M NaCl (physiological solution). A simulation box covering the
entire enzyme system was introduced with a 10 Å buffer space. The
simulation was run for 100 ns at 300 K and standard pressure
(1.01325 bar). The target complex trajectory analysis for interacting
residues and was conducted using the Desmond software [10].
Target library preparation. A virtual library of n = 5903 drug
compounds was downloaded from the latest Zinc database [11] under
the ‘world’ subset (approved drugs in major jurisdictions, including the
FDA, i.e DrugBank approved). The database was then checked for
redundancy, and duplicates were removed. Ligand preparation was
performed using LigPrep, which generated variations of the ligands,
eliminated reactive species, and optimized the ligands. Optimization
was performed under the OPLS3e force field. EPIK minimization was
performed on possible states at pH 7.0 ± 2.0. Tautomers were generated
for each ligand retaining specific chirality combinations with a
maximum of 32 structures per ligand [10].
Receptor grid generation. COACH analysis was performed to deter
mine the location and size of the active site [137]. The shape and
properties of the receptor are represented on a grid to ensure that
possible active compounds are not missed. The centroid of the COACH
predicted binding pocket residues and was used to generate grids using
default values of protein atom scaling (1.0 Å) within a cubic box and
ligand docking set to a length of 20 Å. The force field employed for grid
generation was OPLS3e [136]. Rotatable groups were automatically
determined by the Receptor Grid Generation wizard of the Glide module
[10]. COACH predicted binding sites for each target were as follows;
Exoribonuclease (ExoN); Based on the active site similarity with PDB ID:
5C8T, S-Adenosyl-L-Methionine (SAM) binding site was selected 292,
333, 335, 352, 353, 366, 367, 368, 385, 386, 387 & 426 PLpro (Papainlike proteinase); Based on PDB similarity with SARS-CoV Plpro model
PDB ID: 3mj5B and catalytic triad of Cys–His–Asp the amino acid grid
site selected was 209, 223, 230, 233, 234, 235, 236, 237, 238, 239, 293,
318, 321, 324, 325, 327, 349, 350, 352, 353, 354, 356 & 763. 3Chymotrypsin-Like Protease (3CLpro); Based on PDB id: 2q6gB the
substrate-binding site was selected comprising of amino acid numbers
25, 26, 27, 41, 49, 140, 141, 142, 143, 144, 145, 163, 164, 165, 166,
168, 172, 187, 189, 190 & 192. 2′ -O-methyltransferase (2′ -O-MT); Based
on similarity with PDB id. 4N48 the SAM binding site was predicted to
be 46, 74, 133, 134, 170 & 203 and was used for grid selection RNAdirected RNA polymerase (RdRP); Based on PDB hit; 3ol9I with similar
active site the nucleic acid binding site was selected comprising of amino
acid side chain residues 500, 501, 507, 512, 543, 545, 557, 559, 560,
569, 580, 589, 590, 591, 592, 682, 683, 684, 685, 686, 758, 857, 860,
864 & 914 Nonstructural Uridylate-specific endoribonuclease (Nen
doU): The COACH hit was PDB id:2C1W and the active site selected was
234, 249, 289, 291, 292, 293, 332, 334, 339, 340, 341 & 342 & Helicase
(Hel): based on the similarity of active site with hit PDB id: 4N0O nucleic
acid binding site was selected comprising of amino acid side chain res
idues 177, 178, 179, 180, 181, 197, 214, 309, 310, 311, 334, 335, 336,
337, 338, 339, 408, 409, 410, 411, 412, 413, 414, 485, 486, 516, 534,
554 & 560
High-Throughput Virtual Screening (HTVS). The screening was
performed with default parameters including ionization states, Epik
state penalties within the Glide (Grid-based ligand docking from ener
getics) module of Schrödinger suite [138]. The scaling factor was
maintained at a default of 0.8 and a partial charge cut-off was limited to
0.15. The OPLS3e force field was used during the docking process. The
HTVS ligand docking was the first to be performed, followed by SP and
XP docking on the top 10% of scoring hits from each previous step. The
XP docking aids in removing false positives and the scoring function is
much stricter than the HTVS. The greater the XP Glide score, the better
the calculated affinity of the hit in binding to the protein target. Further,
the estimation of free binding energies for the best hit-docked complexes
using MM force fields and implicit solvation was performed using the
molecular mechanics/generalized Born surface area (MM-GBSA)
method within the virtual screening workflow of Schrödinger suite [10].

The binding energy was calculated based on the following equation.
ΔG = E_complex(minimized) − (E_ligand(minimized) + E_receptor
(minimized))
The leads were ranked based on the binding free energy calculation
for their respective protein-ligand complexes.
Molecular Dynamics Simulation (MDS). To determine the stability
of the ligand-receptor complex especially during flexibility of the
binding site and to determine the energetic strain on the docked ligand
that could result in immediate fly off (<10 ns). The top hit for each
target was subjected to a 20 ns MD simulation (100 ns for XAV939 + 3CLpro, BIM IX + 3CLpro, & BIM IX + ExoN) as described above
in the Target/receptor Preparation section to validate the interaction
and thereby the HTVS pipeline and MM-GBSA performance. If the top
hit flew off immediately due to major conformation change in the re
ceptor site then the receptor was stimulated alone for 20 ns to reach a
stable state and screening was repeated with the resulting minimized
structure.
In-vitro microneutralization assay. BIM IX was shortlisted for its
predicted affinity for both 3CLpro (Main protease) and ExoN (Exonu
clease) active site. Ivermectin was included as a positive control. Other
shortlisted molecules included RdRP hits (paromomycin, amikacin, and
lactulose), 3CLpro hits (iopromide & troxerutin), and one NendoU hit
(haloperidol).
In vitro studies on SARS-CoV-2 were performed at the United States
Army Medical Research Institute for Infectious Diseases (USAMRIID).
Both entry and spread assays were performed on ATCC Vero E6 cells
infected with the SARS-CoV-2 virus. Entry Assay: Vero E6 cells, in 96
well plates, were pre-treated with 14 different test compounds starting
at a concentration of 50 μM with 3 fold dilutions down to 0.76 nM for
approximately 1hr at 37 ◦ C. SARS-CoV-2/MT020880 was then added to
the test compound treated cells for 1 h. at 37 ◦ C at an MOI of 0.4. After
1 h., the cells were washed with PBS before adding additional com
pounds back in fresh culture media to the cells for 24 h. at 37 ◦ C. Cell
media was removed and washed with PBS and plates were submerged in
the formal fixing solution for 24 h., then permeabilized with 0.2%
Triton-X for 10 min at RT and treated with blocking solution (3% BSA/
PBS). Infected cells were detected using a primary detection antibody
recognizing the SARS-CoV-2 nucleocapsid protein (Sino Biological,
40143-R001) and Alexa Fluor 488 conjugated antibody (goat α rabbit),
then counterstained with DAPI for visualization of the cell nuclei.
Infected cells were enumerated using the Operetta high content imaging
instrument and data analysis was performed using the Harmony soft
ware (Perkin Elmer). Spread Assay: A similar protocol was utilized to
the entry assay described above with the following modifications. The
virus was used at an MOI of 0.02 and the assay was incubated for 48 hrs.
rather than 24 hr. after infection of the cells.
Compound screening to identify 3CLpro inhibitors. Assays were
performed in duplicate at room temperature in 96-well black plates at
25 ◦ C. Reactions containing varying concentrations of inhibitor
(1–50 µM) and 3CLpro enzyme (0.4 µM) in Tris-HCl pH 7.3, 1 mM EDTA
were incubated for approximately five minutes. Reactions were then
initiated with TVLQ-AMC probe substrate (40 µM), shaken linearly for
5 s, and then measured for fluorescence emission intensity (excitation λ:
364 nm; emission λ: 440 nm) over time (1 min-3 h) on a Synergy Neo2
Hybrid. Each assay contained 6–8 positive control wells (DMSO
replacing inhibitor) and 2 negative control wells (assay components
without 3CLpro).
3CLpro enzyme inhibition assay. Fluorescence-based biochemical
assay for inhibitors of 3CLpro. Inhibition assays were performed in 96well black plate in triplicate at 25 ◦ C. Reactions containing varying
concentrations of inhibitor (0–1000 µM) and 3CLpro enzyme (0.4 µM) in
Tris-HCl pH 7.3, 1 mM EDTA were incubated for approximately five
minutes. Reactions were then initiated with TVLQ-AMC probe substrate
(40 µM), shaken linearly for 5 s, and then measured continuously for
fluorescence emission intensity (excitation λ: 364 nm; emission λ:
440 nm). Data were fit using nonlinear regression (dose-response
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inhibition, variable slope) analysis in GraphPad Prism 7.0.
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